Weekly Digest – August 2025 Weekly Digest – August 2025 12 August 2025: UAE fast-tracks approval of Blenrep, pioneering treatment for multiple myeloma The UAE has approved Blenrep (Belantamab Mafodotin) as a treatment for relapsed or resistant multiple myeloma UAE […]
Weekly Digest – August 2025 Weekly Digest – August 2025 11 August 2025: Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma Junshi Bioscience’s supplemental new drug application (sNDA) for toripalimab […]
Weekly Digest – August 2025 Weekly Digest – August 2025 12 August 2025: PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery PADCEV plus KEYTRUDA is the first regimen to significantly […]
Weekly Digest – August 2025 Weekly Digest – August 2025 12 August 2025: Idience and Aptis collaborate to develop next-generation dual payload ADC cancer drug Idience and Aptis have signed a joint development agreement to create next-generation dual payload antibody-drug […]
Weekly Digest – August 2025 Weekly Digest – August 2025 12 August 2025: Cohance Lifesciences announces $10 M investment in cGMP Bioconjugation Suite in US Cohance Lifesciences is investing $10 million to expand cGMP bioconjugation capabilities at its US-based subsidiary, […]
Weekly Digest – August 2025 Weekly Digest – August 2025 09 August 2025: Ipsen hands back Sutro’s ROR1 ADC at center of $875M deal Ipsen has exited an $875 million deal with Sutro Biopharma for the ROR1-targeted antibody-drug conjugate (ADC) […]
Weekly Digest – August 2025 Weekly Digest – August 2025 04 August 2025: Alphamab Oncology announces IND application for innovative PD-L1/αvβ6 bispecific ADC JSKN022 was officially accepted by CDE Alphamab Oncology’s IND application for JSKN022, a first-in-class PD-L1/αvβ6 bispecific ADC, […]
Weekly Digest – August 2025 Weekly Digest – August 2025 01 August 2025: Mabwell announces IND application acceptance for CDH17-targeting ADC 7MW4911 from both NMPA and FDA Mabwell’s proprietary CDH17-targeting ADC 7MW4911 received IND acceptance from China’s NMPA and IND […]
Weekly Digest – August 2025 Weekly Digest – August 2025 07 August 2025: Henlius to initiate a Phase 1 multicenter study in US of its PD-L1 ADC HLX43 for the treatment of thymic carcinoma The U.S. FDA has approved Henlius to initiate a Phase 1 multicenter trial of […]
Weekly Digest – August 2025 Weekly Digest – August 2025 08 August 2025: Antengene’s ATG-022 clinical study achieves positive results, CR achieved in elderly gastric cancer patient In Antengene’s Phase 1/2 CLINCH study, its in-house CLDN18.2-targeting ADC ATG-022 achieved a […]
